Celldex Therapeutics, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Celldex Therapeutics, Inc. (CLDX) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $8.86 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-02-25
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $8.86M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $20.94M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $14.67M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $9.99M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $8.86M 10-K · filed 2026-02-25 |
| 2024-12-31 | $20.94M 10-K · filed 2026-02-25 |
| 2023-12-31 | $14.67M 10-K · filed 2025-02-27 |
| 2022-12-31 | $9.99M 10-K · filed 2024-02-26 |
| 2021-12-31 | $14.72M 10-K · filed 2023-02-28 |
| 2020-12-31 | $13.20M 10-K · filed 2022-02-28 |
| 2019-12-31 | $12.65M 10-K · filed 2021-03-29 |
| 2018-12-31 | $11.98M 10-K · filed 2020-03-26 |
| 2017-12-31 | $10.72M 10-K · filed 2019-03-07 |
| 2016-12-31 | $12.36M 10-K · filed 2018-03-07 |
| 2015-12-31 | $8.39M 10-K · filed 2017-03-14 |
| 2014-12-31 | $5.56M 10-K/A · filed 2016-02-25 |
| 2013-12-31 | $3.93M 10-K · filed 2015-02-24 |
| 2012-12-31 | $3.26M 10-K · filed 2014-03-03 |
| 2011-12-31 | $3.18M 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |